CN101854957B - 放射性氟化方法 - Google Patents

放射性氟化方法 Download PDF

Info

Publication number
CN101854957B
CN101854957B CN2008801157351A CN200880115735A CN101854957B CN 101854957 B CN101854957 B CN 101854957B CN 2008801157351 A CN2008801157351 A CN 2008801157351A CN 200880115735 A CN200880115735 A CN 200880115735A CN 101854957 B CN101854957 B CN 101854957B
Authority
CN
China
Prior art keywords
compound
formula
mmol
peptide
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801157351A
Other languages
English (en)
Chinese (zh)
Other versions
CN101854957A (zh
Inventor
A·卡思伯森
M·索尔巴肯
D·E·奥尔伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN101854957A publication Critical patent/CN101854957A/zh
Application granted granted Critical
Publication of CN101854957B publication Critical patent/CN101854957B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN2008801157351A 2007-09-10 2008-09-09 放射性氟化方法 Expired - Fee Related CN101854957B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97100707P 2007-09-10 2007-09-10
US60/971,007 2007-09-10
PCT/US2008/075684 WO2009035959A2 (en) 2007-09-10 2008-09-09 Radiofluorination methods

Publications (2)

Publication Number Publication Date
CN101854957A CN101854957A (zh) 2010-10-06
CN101854957B true CN101854957B (zh) 2013-05-22

Family

ID=40343591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801157351A Expired - Fee Related CN101854957B (zh) 2007-09-10 2008-09-09 放射性氟化方法

Country Status (5)

Country Link
US (1) US8444955B2 (enExample)
EP (1) EP2195037A2 (enExample)
JP (1) JP5318874B2 (enExample)
CN (1) CN101854957B (enExample)
WO (1) WO2009035959A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB201020314D0 (en) * 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
GB201201062D0 (en) 2012-01-23 2012-03-07 Ge Healthcare Ltd Radiofluorination method
CN103665114B (zh) * 2012-09-25 2015-08-05 国家纳米科学中心 一种肽及其制备方法和用途以及药物组合物及其制备方法
JP2016518311A (ja) * 2013-03-08 2016-06-23 ユニヴァーシティー オブ サザン カリフォルニア ビニルスルホン系１８ｆ標識化組成物ならびにその方法およびその使用
GB201308053D0 (en) 2013-05-03 2013-06-12 Ge Healthcare Ltd Metal complexes and fluorination thereof
WO2016087653A1 (en) * 2014-12-04 2016-06-09 Ge Healthcare Limited Method of removing acetaldehyde from radioactive pharmaceuticals
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225038C2 (de) * 1992-07-29 1995-11-30 Boehringer Mannheim Gmbh Herstellung und Verwendung von Antikörpern gegen Kollagen
JP3596041B2 (ja) * 1994-09-09 2004-12-02 住友化学工業株式会社 Ｏ−アルキル−Ｎ−（β−ニトロエチル）ヒドロキシルアミン誘導体およびその製造方法
AU6317996A (en) * 1995-07-07 1997-02-10 Sagami Chemical Research Center Peptide derivatives and angiotensin iv receptor agonist
JP2002049136A (ja) * 2000-05-25 2002-02-15 Konica Corp ハロゲン化銀感光材料および特定のヒドロキシルアミン化合物
WO2004106941A2 (en) * 2003-05-30 2004-12-09 Genova Ltd. Secreted polypeptide species associated with cardiovascular disorders
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
WO2008083191A2 (en) * 2006-12-28 2008-07-10 Ge Healthcare As Radiofluorination methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dag Erlend Olberg et al.A Novel Prosthetic Group for Site-Selective Labeling of Peptides for Positron Emission Tomography.《Bioconjugate Chem.》.2008,第19卷(第6期),1301–1308. *
Michael R. Carrasco et al.Chemoselective Alkylation of N-Alkylaminooxy-Containing Peptides.《ORGANIC LETTERS》.2006,第8卷(第16期),3529-3532. *
Steven J. Bark et al.A Highly Efficient Method for Site-Specific Modification of Unprotected Peptides after Chemical Synthesis.《Journal of the American Chemistry Society》.2000,第122卷(第15期),3567-3573. *

Also Published As

Publication number Publication date
EP2195037A2 (en) 2010-06-16
US8444955B2 (en) 2013-05-21
JP5318874B2 (ja) 2013-10-16
JP2010539091A (ja) 2010-12-16
WO2009035959A2 (en) 2009-03-19
CN101854957A (zh) 2010-10-06
US20100196270A1 (en) 2010-08-05
WO2009035959A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CN101854957B (zh) 放射性氟化方法
AU2004218879B2 (en) Methods of radiofluorination of biologically active vectors
CN101084020A (zh) 放射性标记方法
Failla et al. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
JP4365223B2 (ja) 放射性フッ素化方法
CN101472614A (zh) 放射性标记方法
KR20090119966A (ko) 진단 영상화제로서의 18ｆ 플루오로-벤조일 표지된 생물학적 활성 화합물, 벤조트리아졸-1-일옥시-벤조일, 2,5-디옥소-피롤리딘-1-일옥시)벤조일 및 트리메틸암모니오-벤조일 전구체
CN101547933A (zh) 用于pet成像的硅衍生物
CN105579434A (zh) 基于乙烯基砜的18f标记组合物和方法及其用途
US20090035215A1 (en) Radiofluorination
US8216548B2 (en) Radiofluorination methods
US20090022664A1 (en) Radiolabelling via fluorination of aziridines
US8241606B2 (en) Synthesis of a radiofluorinated peptide using photolabile protecting groups
CN117320759A (zh) 放射性药物生长抑素受体配体及其前体
CA2687974A1 (en) Labelling methods
CN119630622A (zh) 用于放射性药物的硅系氟化物受体基团
CN101578262A (zh) 经吖丙啶氟化进行的放射性标记

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130522

Termination date: 20140909

EXPY Termination of patent right or utility model